ArticleInfection and drug resistance2017
Clinical outcomes and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant
Article in Infection and drug resistance, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Factors affecting the effectiveness and safety of colistin in treating drug-resistant gram-negative bacterial infections: a meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Safety Profiles of Polymyxins, Aminoglycosides, and Imipenem/Cilastatin/Relebactam (IMI/REL) in the Treatment of Gram-Negative Infections: A Literature Review.Antibiotics (Basel, Switzerland) · 2026Review
- Treatment of infections caused by carbapenem-resistantFrontiers in cellular and infection microbiology · 2024Review
- Risks of Polymyxin B Nephrotoxicity and Its Precursors in the Intensive Care Unit: A Retrospective Cohort Study.Cureus · 2023Article
- Bacterial Infections and Cancer: Exploring This Association And Its Implications for Cancer Patients.International journal of molecular sciences · 2023Review
- Individualized optimization of colistin loading doses.Journal of pharmacokinetics and pharmacodynamics · 2023Article
- Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-ResistantJournal of clinical medicine · 2022Review
- Pharmacological agents for the prevention of colistin-induced nephrotoxicity.European journal of medical research · 2022Review
- The necessity of a loading dose when prescribing intravenous colistin in critically ill patients with CRGNB-associated pneumonia: a multi-center observational study.Critical care (London, England) · 2022Observational
- Nephrotoxicity and Efficacy Assessment of Polymyxin B Use in Renal Transplant Patients.Infection and drug resistance · 2022Article
- Investigation of Effect of the Colistin Loading Dosage on the clinical, Microbiological, and Laboratory Results inInternational journal of clinical practice · 2022Article
- Nomogram Analysis of Clinical Characteristics and Mortality Risk Factor of Non-Fermentative Gram-Negative Bacteria-Induced Post-Neurosurgical Meningitis.Infection and drug resistance · 2022Article
- Molecular Characterization of Carbapenem-ResistantInfection and drug resistance · 2022Review
- Clinical Efficacy and Nephrotoxicity of the Loading Dose Colistin for the Treatment of Carbapenem-ResistantPharmaceutics · 2021Article
- Colistin-Induced Acute Kidney Injury and the Effect on Survival in Patients with Multidrug-Resistant Gram-Negative Infections: Significance of Drug Doses Adjusted to Ideal Body Weight.International journal of nephrology · 2021Article
- Evaluation of prognosis and nephrotoxicity in patients treated with colistin in intensive care unit.Renal failure · 2020Article
- Nosocomial infections due to multidrug-resistant bacteria in cancer patients: a six-year retrospective study of an oncology Center in Western China.BMC infectious diseases · 2020Observational
- Differences in Colistin Administration and Bacterial and Treatment Outcomes in Critically Ill Patients.Scientific reports · 2019Article
- Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity.Antibiotics (Basel, Switzerland) · 2019Review
- Extensively drug-resistantInfection and drug resistance · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColistin is a last-line defense therapy against extensively drug-resistant PATIENTS AND
methodsA retrospective cohort study of cancer patients who received either a loading or non-loading dose of colistin for treatment of XDR-AB was conducted. For each group, the clinical response, bacteriological eradication and serum creatinine were recorded. Logistic regression was applied to evaluate the effects of therapy on each of the three aforementioned outcomes.
resultsOne hundred and two patients diagnosed with XDR-AB infections between January 2012 and December 2015 were recruited. Only 75 patients were given a loading dose of colistin. There was no significant clinical and microbiological response in patients in the loading dose group or patients in the non-loading dose group. However, 38 (50.67%) patients in the loading dose group and 6 (22.22%) patients in the non-loading dose group developed nephrotoxicity according to the RIFLE criteria (
conclusionAdministration of colistin loading dose did not significantly increase clinical response, microbiological response or mortality rate compared to non-loading dose in cancer patients with XDR-AB-related infections. However, nephrotoxicity was significantly higher when patients received loading dose colistin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.